Search for: "Waxman v. Waxman & Associates, Inc."
Results 41 - 60
of 102
Sorted by Relevance
|
Sort by Date
1 Dec 2010, 5:54 pm
Title: PLIVA, Inc. v. [read post]
9 Jan 2012, 6:24 pm
Supreme Court’s June 23, 2011, 5-4 landmark decision in PLIVA Inc. v. [read post]
25 Jul 2008, 2:11 am
In Ortho-McNeil Pharmaceutical, Inc. v. [read post]
25 Oct 2008, 12:03 am
Sandoz, Inc (Law360) (Hal Wegner) (Patently-O) (Patent Prospector) (PLI) Cipro (Ciprofloxacin) - US: CAFC finds no antitrust liability for Hatch-Waxman reverse payment settlements: In Re Ciproflaxacin Hydrochloride Antitrust Litigation (IP Law Observer) Lescol (Fluvastatin) - US: Mylan confirms first-to-file patent challenge to Lescol by Novartis (SmartBrief) Levaquin (Levofloxacin) - UK: Levofloxacin SPC valid: Generics (UK) Ltd v Daiichi Pharmaceutical Co Ltd… [read post]
31 Oct 2013, 5:00 am
Medtronic, Inc., 552 U.S. 312 (2008); finding PMA preemption under Medtronic, Inc. v. [read post]
21 Oct 2009, 6:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) – US: Shire… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with… [read post]
23 Dec 2011, 6:30 am
Third, in Association for Molecular Pathology v. [read post]
28 Dec 2010, 10:58 am
USA, Inc. v. [read post]
3 Jul 2007, 10:47 am
Teleflex Inc., 127 S. [read post]
27 May 2011, 8:56 am
Cir.)Petition for certiorariBrief in oppositionPetitioner's reply10-627Title: Extreme Networks, Inc. v. [read post]
5 Aug 2021, 12:12 pm
USA, Inc. v. [read post]
13 May 2012, 4:46 pm
Hospira, Inc. [read post]
24 Jun 2014, 8:35 am
Waxman Statement on Supreme Court's Decision in UARG v. [read post]
18 Jan 2013, 2:06 pm
The Decherts are too involved in this litigation to comment publicly.There aren’t many research-oriented pharmaceutical companies based in Alabama, and after last week’s execrable decision in Wyeth, Inc. v. [read post]
7 Apr 2010, 4:30 am
– Myriad stock prices: Association of Molecular Pathology v USPTO (Innovationpartners) US: Federal judge in Myriad patent case says invalidation of gene patents does not violate TRIPS: Association of Molecular Pathology v USPTO (KEI) US: ACLU gene patent decision from an investor’s perspective: A black eye for the US patent system: Association of Molecular Pathology v USPTO (Holman's Biotech IP Blog) US: Association of… [read post]
19 May 2010, 6:47 am
(all) Amicus brief of the Cato Institute et al. (09-988) Amicus brief of eight states (09-991) Title: PLIVA, Inc. v. [read post]
24 Mar 2011, 12:53 pm
Note: Goldstein, Howe & Russell, P.C. serves as counsel to the petitioners in the following case, which is listed without regard to its likelihood of being granted.Title: Kaiser Eagle Mountain, Inc. v. [read post]
15 Apr 2014, 9:29 am
To be sure, the Court has barred suits against generic manufacturers in two decisions following up on Wyeth (PLIVA, Inc. v. [read post]
